UNITED STATES — Albert Bourla, Pfizer's CEO, said on Monday that the company may move overseas drug manufacturing back to the US if President Donald Trump's tariffs affect it.
Bourla was speaking at TD Cowen's annual healthcare conference when he was asked about the impact Trump's tariffs could have on Pfizer's operations. While most of Pfizer's generic drugs are produced overseas, Bourla said the company has a large manufacturing network in the US... businessinsider.com
Share Your Thoughts